As pharmaceutical companies navigate increasing market pressure and leaner budgets, long-standing sales models are undergoing critical re-evaluation. Among them, the traditional model of engaging healthcare professionals (HCPs) through in-person visits is losing traction—not because the connection isn’t valuable, but because the cost structure no longer adds up. 

“Face-to-face visits were once the gold standard in pharma promotion,” says Didem Aral, founder and CEO of reprai. “Today, that standard is shifting. When those visits average just 3 to 5 minutes, the ROI becomes hard to defend—especially when more scalable alternative exists.”

The High Price of In-Person

Travel expenses, scheduling delays, and availability are just a few of the factors that constrain in-person visits. For larger pharma organizations with broad portfolios or decentralized HCP targets, these costs can quickly become unsustainable. 

reprai - a digital, AI-powered engagement platform - tackles this head-on. It enables pharma teams to connect with HCPs anytime, anywhere, significantly reducing the overhead and inefficiencies associated with traditional field force activities.

From One-to-One to One-to-Many

This shift toward asynchronous, always-on engagement is not just about reducing costs. It’s a strategic evolution.

Pharma companies adopting digital-first models are seeing measurable gains in reach, consistency, and responsiveness—especially as HCP expectations evolve in line with consumer-grade digital experiences.

“This isn’t just about automation,” Aral notes. “It’s about creating a new experience—one that respects the time of healthcare professionals while giving pharma teams better tools to support, inform, and educate.”

As the industry evolves, companies that embrace intelligent, digital-first engagement models are not only cutting costs but also building stronger, more consistent connections with their audiences.

The future of pharma engagement isn’t just digital—it’s intelligent, responsive, and scalable. With reprai, that future is already here—empowering pharma teams to scale outreach, streamline operations, and reimagine HCP engagement, one interaction at a time.

Original article: https://www.pharmavoice.com/press-release/20250421-the-new-math-of-hcp-engagement-cutting-costs-not-connections/

A groundbreaking solution, reprai now challenges outdated methods and promises to increase the efficiency of pharma marketing and sales by introducing the first AI-powered solution to the industry. reprai is an AI-powered platform designed to autonomize and optimize the promotional operations of pharma companies. 

The core AI- reREP mimics the duties of a pharma sales representative, while reTOOLS enhances operational efficiency. Together, they provide a comprehensive solution to transform how pharmaceutical companies reach and engage with HCPs (Healthcare Professionals).

“The pharmaceutical industry faces a uniquely challenging promotional landscape. Despite significant technological advances in medical science, the methods used to communicate these advances to healthcare professionals have remained unchanged and now are outdated and inefficient.” says Didem Aral, Founder and CEO of reprai.

Enhancing Efficiency in the Pharma Promotional Landscape

Marketing and sales outcomes often depend on a combination of sales representative visits, digital campaigns, peer influence, and clinical guidelines, making clear attribution difficult. According to an industry research 76% of pharma companies struggle to associate sales results with specific marketing and sales activities.

Additionally, the increasing difficulty for sales representatives meeting with HCPs shows similarity how the digital evolution in our daily lives impacted our expectations. 

Adapting to the new world

reprai’s digital-first approach allows pharmaceutical companies to connect with HCPs from one to many, all at the click of a button. With round-the-clock availability, HCPs have the flexibility to connect on their schedule, whether early morning or late at night. 

This 24/7 accessibility means that companies can expand their engagement footprint without added strain, delivering personalized, relevant information and resources to multiple HCPs simultaneously.

reprai introduces a new era of communication between pharma and healthcare professionals (HCPs), making interactions more to the point, efficient, and up to date.

Will All Pharma Sales Representatives Lose Their Jobs?

Rather than eliminating the pharmaceutical sales workforce, reprai represents a transformation of the industry. Initially, AI representatives can function as standalone entities or be integrated alongside existing teams, augmenting human capabilities rather than entirely replacing them. Sales representatives who excel at their roles will evolve into trainers and specialized experts, guiding the AI systems and handling more complex interactions.

"This transformation is inevitable in the pharmaceutical industry, just as technology reshapes other sectors" explains Didem Aral. "The most successful organizations will be those that effectively blend human expertise with AI capabilities."

Original article: https://www.pharmavoice.com/press-release/20250310-reprai-launches-first-ai-sales-representative-for-pharma/

reprai has launched a groundbreaking AI-powered solution designed to streamline and supercharge pharma marketing and sales in a move that could shake up the pharmaceutical industry. This platform enhances how drug companies interact with healthcare professionals (HCPs).

reprai’s AI-powered platform automates and optimizes promotional operations for pharmaceutical companies. The platform’s core AI, reREP, takes on the role of a traditional pharma sales representative, while reTOOLS boosts operational efficiency. Together, they offer a comprehensive solution to transform pharma companies’ engagement with HCPs.

“The pharmaceutical industry faces a uniquely challenging promotional landscape. Despite significant technological advances in medical science, the methods used to communicate these advances to healthcare professionals have remained unchanged and now are outdated and inefficient,” says Didem Aral Founder and CEO of reprai.

Enhancing Efficiency in the Pharma Promotional Landscape

Marketing and sales outcomes often depend on a combination of sales representative visits, digital campaigns, peer influence, and clinical guidelines, making clear attribution difficult. Industry research suggests that many pharma companies face challenges linking sales results to specific marketing and sales activities. Additionally, the increasing difficulty for sales representatives to meet with HCPs is similar to how the digital evolution in our daily lives has impacted our expectations.

Embracing the Digital Age

reprai’s digital-first approach empowers pharma companies to connect with numerous HCPs at the click of a button. With 24/7 availability, HCPs can engage with the platform whenever it suits their schedule, whether early in the morning or late at night. This round-the-clock accessibility allows companies to expand their reach without additional strain, simultaneously delivering personalized, relevant information and resources to multiple HCPs.

reprai introduces a new era of communication between pharma and HCPs, making interactions more efficient, up-to-date, and to the point.

Will All Pharma Sales Representatives Lose Their Jobs?

Instead of replacing the pharmaceutical sales workforce, Reprai introduces a shift in the industry’s approach. AI representatives will initially work alongside existing teams, supporting their efforts rather than taking over entirely. Sales representatives with strong expertise may take on roles as trainers and specialists, overseeing AI systems and managing more complex interactions.

“This transformation is inevitable in the pharmaceutical industry, just as technology is reshaping other sectors,” says Didem Aral. “The most successful organizations will be those that effectively blend human expertise with AI capabilities.”

Background Behind the Innovation

Founded in 2024, reprai operates as a B2B SaaS solution in the pharmaceutical industry, bringing together expertise and cutting-edge technology. The company comprises seasoned founders with deep knowledge of the pharmaceutical industry, enabling the platform to address real-world challenges faced by actual pharma companies and HCPs.

Founder and CEO Didem Aral brings nearly 25 years of experience in marketing and creative industries to the venture. Her career spans traditional and digital platforms, including significant work with pharma giants such as Pfizer, Johnson & Johnson, MSD, Merck, Novo Nordisk, Takeda, and Bayer.

Her extensive background in medico-marketing and HCP communications provides an excellent basis for developing a solution that truly meets the needs of the pharmaceutical industry.

Published by Anne C.

Original article: https://nyweekly.com/health/reprai-launches-ai-powered-solution-designed-for-pharma/

For decades, pharma companies have relied on sales visits as the primary channel to engage with doctors, believing that these interactions shape prescribing behaviors. However, the reality of modern medical decision-making has evolved, and the actual impact of sales visits remains unclear.

Notably, a recent report emphasizes that customer experience accounts for 35% of prescription decision-making. This underscores the importance for pharmaceutical companies to move beyond conventional sales visits and focus on delivering high-quality, evidence-based information that aligns with HCPs' needs.

Doctors operate in a complex environment where multiple factors influence their choices. Drug formularies, clinical pathways, R&D advancements, and updates from clinical trials play a crucial role in prescribing decisions. Yet, pharma companies often focus on traditional promotional tactics, assuming that doctors prioritize direct engagement over evidence-based practice.

In today’s landscape, healthcare professionals are increasingly turning to digital resources, peer-reviewed studies, and real-world data rather than relying solely on sales representatives. Clinical trial results, safety profiles, and cost-effectiveness assessments are more influential than ever. Furthermore, regulatory pressures and hospital policies limit the direct impact of in-person visits, making it imperative for pharma companies to rethink their engagement strategies.

Pharma must shift toward more personalized, data-driven, and value-based communication to truly understand what doctors want. Providing relevant, timely, and scientifically robust information through digital channels, on-demand content, and AI-driven insights can foster a more meaningful connection with HCPs.

The industry must ask itself: Are we engaging doctors in the way they need, or in the way we assume they want? The future of pharma-doctor interactions depends on aligning with the evolving needs of healthcare professionals rather than clinging to outdated models of influence.

This year, the pharmaceutical industry finds itself at a pivotal moment. Marketing and sales strategies are evolving rapidly to keep pace with groundbreaking technological advancements, altering communication channels, and rising expectations from healthcare professionals (HCPs). Here’s a closer look at how the landscape is transforming and what it means for the future.

ROI: The Cornerstone of 2025 Strategies

Return on Investment (ROI) has always been a key performance indicator, but its significance has reached unprecedented levels in 2025. With tighter budgets and fiercer competition, every dollar spent must deliver measurable value. Yet, many pharmaceutical companies still face challenges in accurately measuring the ROI of their marketing efforts.

A recent Deloitte report reveals that only 35% of healthcare companies can confidently link marketing spending to specific outcomes. This shortfall is largely due to fragmented data systems, the absence of integrated analytics tools, and outdated methods for evaluating success.

To close this gap, advanced technologies like AI-powered analytics platforms and machine learning models are becoming indispensable. These technologies not only monitor performance metrics in real-time but also provide predictive insights to inform smarter decision-making. In 2025, pharma companies that prioritize investments in these technologies will be best positioned to stay ahead of the curve.

The Rise of Effective Working

Efficiency is no longer just a buzzword; it’s a business imperative. In 2025, effective working means integrating tools and workflows to drive productivity and performance. Pharma companies are increasingly adopting autonomous platforms to streamline promotional activities, minimizing manual tasks and freeing up teams to focus on high-impact initiatives like strategy development and personalized outreach.

One standout approach is the adoption of hybrid marketing models that blend traditional and digital strategies. These models preserve the personal connection of face-to-face interactions while harnessing the scalability and precision of digital channels. Platforms like reprai are redefining industry standards by seamlessly integrating these methods, enabling deeper HCP engagement, and delivering measurable results.

Time Management: A Competitive Advantage

In an era of rapid innovation, time management has emerged as a key competitive advantage. Pharma companies that optimize workflows can achieve faster go-to-market timelines and greater agility in meeting HCP needs. By automating repetitive tasks and leveraging AI-powered assistants, organizations can reclaim valuable time and focus on strategic priorities.

For example, reprai’s 24/7 model ensures continuous availability, enabling companies to support HCPs beyond the limits of traditional working hours. This approach not only boosts operational efficiency but also expands the reach of doctor interactions scaling from one to many without adding resource burdens.

Understanding HCP Needs: The Key to Success

Effective communication starts with knowing your audience. In 2025, healthcare professionals (HCPs) expect information that is tailored, relevant, and delivered at the right time. Generic, one-size-fits-all strategies are no longer enough. According to a McKinsey study, 80% of HCPs prefer communication channels that match their personal preferences, yet only 45% of pharma companies actively personalize their outreach.

The answer lies in harnessing HCP insights. AI-powered platforms can analyze interaction data to uncover preferences, anticipate needs, and deliver highly personalized content. By prioritizing these insights, pharma companies can strengthen relationships, build trust, and ultimately achieve better outcomes.

Companies that embrace these trends won’t just succeed in 2025 they’ll lay the foundation for long-term, sustainable growth.

The debate over the ideal frequency of pharmaceutical sales calls has persisted for years. While traditional strategies emphasize quantity and maximizing in-person visits, the modern healthcare landscape calls for a more strategic and flexible approach.

Historically, pharmaceutical sales representatives aimed to pack their schedules with 8–10 in-person meetings daily. The rationale was straightforward: the more in-person interactions, the higher the likelihood of driving prescriptions. However, this volume-driven model is becoming increasingly outdated in today’s rapidly changing healthcare environment.

A Strategic Approach to Call Frequency

Limited Access

Physicians face increasing time pressures and administrative responsibilities, making frequent in-person meetings more challenging than ever. Over the past decade, studies have repeatedly shown a steady decline in access to pharmaceutical sales representatives.¹

On average, sales calls last only 5–10 minutes, underscoring the need for concise, impactful communication.²

Digital Channels

The emergence of digital communication has created new opportunities for engaging healthcare professionals (HCPs). Industry reports reveal a growing trend among pharmaceutical companies toward virtual meetings and using online content to inform and build relationships.³

Value-Driven Interactions

Healthcare professionals (HCPs) now prioritize engagements that provide meaningful insights and directly contribute to patient care. Research shows that many physicians prefer email as a communication channel, highlighting the growing importance of digital touchpoints.⁴

In today’s dynamic healthcare landscape, success hinges on striking the right balance between in-person and digital interactions. Emerging technologies, such as AI-powered platforms like reprai, are reshaping how pharmaceutical companies engage with HCPs. These tools enable 24/7 access to information, deliver personalized content, and create virtual engagement opportunities, enhancing both the frequency and quality of communication.

By leveraging technology and embracing innovative, value-driven strategies, pharmaceutical companies can navigate the complexities of modern HCP engagement. A digital-first approach will not only adapt to evolving trends but also ensure stronger, more meaningful connections with healthcare professionals, empowering them to deliver better patient care.

Sources:

1. ZS Associates AccessMonitor™ (zs.com)

2. Pharmaceutical Executive (pharmexec.com)

3. Veeva, Digital Trends in the Life Sciences Industry, 2023

4. DRG Digital, "ePharma Physician® Report", 2021